Familial Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma: Epidemiology, Risk Factors, and Biological Characteristics

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2012 Feb 23

PMID 22354002

Citations 27

Authors

Alexandra J Greenberg

S Vincent Rajkumar

Celine M Vachon

Affiliations

Soon will be listed here.

Abstract

Monoclonal gammopathy of undetermined significance (MGUS), a precursor to multiple myeloma (MM), is one of the most common premalignant conditions in the general population. The cause of MGUS is largely unknown. Recent studies show that there is an increased prevalence of MGUS in blood relatives of persons with lymphoproliferative and plasma cell proliferative disorders, suggesting presence of shared underlying genetic influences. In the past few years, additional studies have examined risk factors and biologic characteristics that may contribute to the increased prevalence of MGUS among relatives of probands with MGUS, MM, and other blood malignancies. This article reviews the known epidemiology and risk factors for familial MGUS and myeloma, the risk of lymphoproliferative disorders and other malignancies among blood-relatives of patients with MGUS and MM, and discusses future directions for research.

Citing Articles

New horizons in our understanding of precursor multiple myeloma and early interception.

Cordas Dos Santos D, Toenges R, Bertamini L, Alberge J, Ghobrial I Nat Rev Cancer. 2024; 24(12):867-886.

PMID: 39414947 DOI: 10.1038/s41568-024-00755-x.

Influence of structural racism on cancer health disparities: Tailoring measures relevant to multiple myeloma.

Roland H, McGuire C, Baskin M, Esposito M, Baker E, Brown E Cancer. 2024; 130(23):4012-4019.

PMID: 39127894 PMC: 11818237. DOI: 10.1002/cncr.35512.

Anthropometric traits and risk of multiple myeloma: differences by race, sex and diagnostic clinical features.

Arnold K, Ong K, Ravi G, Cutshall H, Purnell K, Wessel M Br J Cancer. 2024; 131(2):312-324.

PMID: 38849476 PMC: 11263363. DOI: 10.1038/s41416-024-02723-6.

Retracted Article: Long non-coding RNA PCAT1 facilitates cell growth in multiple myeloma through an MTDH-mediated AKT/β-catenin signaling pathway by sponging miR-363-3p.

Chen Y, Hao J, Zhao J, Liu Y, Li Y, Ren J RSC Adv. 2022; 9(58):33834-33842.

PMID: 35528923 PMC: 9073615. DOI: 10.1039/c9ra06188f.

Genome-wide meta-analysis of monoclonal gammopathy of undetermined significance (MGUS) identifies risk loci impacting IRF-6.

Clay-Gilmour A, Chattopadhyay S, Hildebrandt M, Thomsen H, Weinhold N, Vodicka P Blood Cancer J. 2022; 12(4):60.

PMID: 35418122 PMC: 9007981. DOI: 10.1038/s41408-022-00658-w.

References

Kang S, Kim T, Kim H, Yoon J, Cho H, Yoon S . Protective role of CYP1A1*2A in the development of multiple myeloma. Acta Haematol. 2008; 119(1):60-4. DOI: 10.1159/000117572. View

Kyle R, Therneau T, Rajkumar S, Larson D, Plevak M, Offord J . Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006; 354(13):1362-9. DOI: 10.1056/NEJMoa054494. View

Brown L, Linet M, Greenberg R, Silverman D, Hayes R, Swanson G . Multiple myeloma and family history of cancer among blacks and whites in the U.S. Cancer. 1999; 85(11):2385-90. View

Horwitz L, Levy R, Rosner F . Multiple myeloma in three siblings. Arch Intern Med. 1985; 145(8):1449-50. View

Landgren O, Katzmann J, Hsing A, Pfeiffer R, Kyle R, Yeboah E . Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana. Mayo Clin Proc. 2007; 82(12):1468-73. DOI: 10.1016/S0025-6196(11)61089-6. View

Ostrovsky O, Korostishevsky M, Levite I, Leiba M, Galski H, Vlodavsky I . Association of heparanase gene (HPSE) single nucleotide polymorphisms with hematological malignancies. Leukemia. 2007; 21(11):2296-303. DOI: 10.1038/sj.leu.2404821. View

Birmann B, Tamimi R, Giovannucci E, Rosner B, Hunter D, Kraft P . Insulin-like growth factor-1- and interleukin-6-related gene variation and risk of multiple myeloma. Cancer Epidemiol Biomarkers Prev. 2009; 18(1):282-8. PMC: 2661109. DOI: 10.1158/1055-9965.EPI-08-0778. View

Lynch H, Sanger W, Pirruccello S, Weisenburger D . Familial multiple myeloma: a family study and review of the literature. J Natl Cancer Inst. 2001; 93(19):1479-83. DOI: 10.1093/jnci/93.19.1479. View

Lynch H, Ferrara K, Barlogie B, Coleman E, Lynch J, Weisenburger D . Familial myeloma. N Engl J Med. 2008; 359(2):152-7. PMC: 2775509. DOI: 10.1056/NEJMoa0708704. View

10.

Bizzaro N, Pasini P . Familial occurrence of multiple myeloma and monoclonal gammopathy of undetermined significance in 5 siblings. Haematologica. 1990; 75(1):58-63. View

11.

Grass S, Preuss K, Thome S, Weisenburger D, Witt V, Lynch J . Paraproteins of familial MGUS/multiple myeloma target family-typical antigens: hyperphosphorylation of autoantigens is a consistent finding in familial and sporadic MGUS/MM. Blood. 2011; 118(3):635-7. DOI: 10.1182/blood-2011-01-331454. View

12.

Skibola C, Bracci P, Halperin E, Conde L, Craig D, Agana L . Genetic variants at 6p21.33 are associated with susceptibility to follicular lymphoma. Nat Genet. 2009; 41(8):873-5. PMC: 2823809. DOI: 10.1038/ng.419. View

13.

Hayden P, Tewari P, Morris D, Staines A, Crowley D, Nieters A . Variation in DNA repair genes XRCC3, XRCC4, XRCC5 and susceptibility to myeloma. Hum Mol Genet. 2007; 16(24):3117-27. DOI: 10.1093/hmg/ddm273. View

14.

Gerkes E, de Jong M, Sijmons R, Vellenga E . Familial multiple myeloma: report on two families and discussion of screening options. Hered Cancer Clin Pract. 2009; 5(2):72-8. PMC: 2736995. DOI: 10.1186/1897-4287-5-2-72. View

15.

Smedby K, Foo J, Skibola C, Darabi H, Conde L, Hjalgrim H . GWAS of follicular lymphoma reveals allelic heterogeneity at 6p21.32 and suggests shared genetic susceptibility with diffuse large B-cell lymphoma. PLoS Genet. 2011; 7(4):e1001378. PMC: 3080853. DOI: 10.1371/journal.pgen.1001378. View

16.

Conde L, Halperin E, Akers N, Brown K, Smedby K, Rothman N . Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32. Nat Genet. 2010; 42(8):661-4. PMC: 2913472. DOI: 10.1038/ng.626. View

17.

Grass S, Preuss K, Ahlgrimm M, Fadle N, Regitz E, Pfoehler C . Association of a dominantly inherited hyperphosphorylated paraprotein target with sporadic and familial multiple myeloma and monoclonal gammopathy of undetermined significance: a case-control study. Lancet Oncol. 2009; 10(10):950-6. DOI: 10.1016/S1470-2045(09)70234-7. View

18.

Landgren O, Gridley G, Turesson I, Caporaso N, Goldin L, Baris D . Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood. 2005; 107(3):904-6. PMC: 1895893. DOI: 10.1182/blood-2005-08-3449. View

19.

Grass S, Preuss K, Wikowicz A, Terpos E, Ziepert M, Nikolaus D . Hyperphosphorylated paratarg-7: a new molecularly defined risk factor for monoclonal gammopathy of undetermined significance of the IgM type and Waldenstrom macroglobulinemia. Blood. 2011; 117(10):2918-23. DOI: 10.1182/blood-2010-09-306076. View

20.

Purdue M, Lan Q, Menashe I, Zheng T, Zhang Y, Yeager M . Variation in innate immunity genes and risk of multiple myeloma. Hematol Oncol. 2010; 29(1):42-6. PMC: 2980579. DOI: 10.1002/hon.954. View